Insider filing
Traded Apr 1 · filed 10 days later
Compensation award — excluded from discretionary-purchase analysis.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Traded Feb 26, 2026 · Filed Mar 12, 2026
Edesa Biotech's President paid $3.1K out of pocket for Edesa Biotech shares. 1 other person at Edesa Biotech bought some too, in the same month.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell.
open market purchase
Code P — open-market or private purchase
~$3,140
Shares × reported transaction price
<$25K
+0.9%
Purchase shares ÷ estimated pre-transaction holdings, from the filing
Not enough history to judge
Confirmed open-market purchases by the same insider in the available history
2 distinct insiders in 30 days
Distinct insiders at the same issuer with confirmed open-market purchases
This purchase equals less than 1% of the average reported total pay of the company's named executive officers other than the CEO, fiscal 2025 ($516K)
An average across the officers named in the pay versus performance table of the company's proxy statement (DEF 14A), filed 2026-04-03. This person may not be one of them, so it is not their own pay. A size comparison, not a judgement
13 days after results of Feb 13, 2026, 77 days before results of May 14, 2026
Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results
Closed at $1.55 on Feb 26, 2026, 94% above its 52-week low and 46% below its high, after a 5% rise over the previous 30 trading days
52-week range $0.80 (Feb 20, 2026) to $2.88 (Oct 6, 2025), 36% of the way up, from 251 adjusted closes. 30 trading days earlier: $1.48 on Jan 13, 2026. Describes the past only, not a forecast
None found in footnotes
Only flagged when a footnote says so; never inferred
The first open-market purchase by any EDSA insider since Mar 2024. Michael J Brooks's first purchase of EDSA since Jun 2022
Compared with every open-market purchase and sale of this company in SEC filings since 2006. A fact about the record, not a signal to trade
| After | Stock | S&P 500 | Difference |
|---|---|---|---|
| 7 days | +13.3% | −0.9% | +14.3% |
| 30 days | −7.5% | +3.0% | −10.5% |
| 90 days | −18.3% | +8.9% | −27.3% |
| 180 days | −25.9% | +15.0% | −40.9% |
Past results only. Not a forecast.
Insider filing
Traded Apr 1 · filed 10 days later
Compensation award — excluded from discretionary-purchase analysis.
Insider buying
Traded Mar 10 · filed 1 day later
The CEO of Edesa Biotech paid $6.6K out of pocket for Edesa Biotech shares. 1 other person at Edesa Biotech bought some too, in the same month.
Insider buying
Traded Mar 5 · filed 2 days later
The CEO of Edesa Biotech paid $39K out of pocket for Edesa Biotech shares. 1 other person at Edesa Biotech bought some too, in the same month.
Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.